Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review

The Lancet Respiratory Medicine

Volumn 2, Issue 4, 2014, Pages 301-320

  Kaufmann, Stefan H E ^a   Lange, Christoph ^b   Rao, Martin ⁱ   Balaji, Kithiganahalli N ^c   Lotze, Michael ^d,e   Schito, Marco ^f   Zumla, Alimuddin I ^g,h   Maeurer, Markus ⁱ  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c INDIAN INSTITUTE OF SCIENCE   (India)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALISPORIVIR; BCG VACCINE; CILOSTAZOL; CLOFAZIMINE; CLOTRIMAZOLE; COLECALCIFEROL; DEXAMETHASONE; ECONAZOLE; ETANERCEPT; HISTONE DEACETYLASE INHIBITOR; IBUPROFEN; IMATINIB; INFLIXIMAB; INTERLEUKIN 24; INTERLEUKIN 4; ISONIAZID; PLACEBO; PREDNISOLONE; PYRAZINAMIDE; PYRIMETHAMINE PLUS SULFADOXINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RIFAMPICIN; SILDENAFIL; THALIDOMIDE; UNINDEXED DRUG; TUBERCULOSTATIC AGENT;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTATION; APOPTOSIS; ARTHRITIS; ASTHMA; AUTOPHAGY; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COUGHING; CUTANEOUS T CELL LYMPHOMA; DEPRESSION; DRUG POTENTIATION; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EPILEPSY; ERECTILE DYSFUNCTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GRANULOMA; HERPES ZOSTER; HISTONE MODIFICATION; HOST DIRECTED THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; LATENT TUBERCULOSIS; LEUKEMIA; LOW DRUG DOSE; LUNG TUBERCULOSIS; MELANOMA; MENTAL DISEASE; MESENCHYMAL STROMA CELL; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NEUROLOGIC DISEASE; NONHUMAN; OFF LABEL DRUG USE; PANDEMIC; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKIN INFECTION; SOLID TUMOR; TUBERCULOSIS; TUBERCULOUS MENINGITIS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; DRUG EFFECTS; IMMUNOLOGY; MEDICAL RESEARCH;

ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84897959389     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70033-5     Document Type: Review

References (213)

1. Moran M, Guzman J, Henderson K, et al. Neglected Disease Research and Development: a five year review 2012, Policy Cures, London.
2. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014, 58:470-480.
3. Koup RA, Douek DC Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med 2011, 1:a007252.
4. Chen K, Kolls JK T cell-mediated host immune defenses in the lung. Annu Rev Immunol 2013, 31:605-633.
5. Lawn SD, Zumla AI Tuberculosis. Lancet 2011, 378:57-72.
6. Collins HL, Kaufmann SH The many faces of host responses to tuberculosis. Immunology 2001, 103:1-9.
7. Cooper AM Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
8. Ulrichs T, Kaufmann SH New insights into the function of granulomas in human tuberculosis. J Pathol 2006, 208:261-269.
9. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
10. Cruz A, Fraga AG, Fountain JJ, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010, 207:1609-1616.
11. Woodworth JS, Behar SM Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. Crit Rev Immunol 2006, 26:317-352.
12. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 2012, 205(suppl 2):S301-S315.
13. Axelsson-Robertson R, Loxton AG, Walzl G, et al. A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis. PLoS ONE 2013, 8:e58309.
14. Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282:121-125.
15. De Libero G, Mori L Recognition of lipid antigens by T cells. Nat Rev Immunol 2005, 5:485-496.
16. Gold MC, Cerri S, Smyk-Pearson S, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010, 8:e1000407.
17. Skjøt RL, Brock I, Arend SM, et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002, 70:5446-5453.
18. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
19. Gengenbacher M, Kaufmann SH Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012, 36:514-532.
20. Reece ST, Kaufmann SH Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis?. Curr Opin Microbiol 2012, 15:63-70.
21. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009, 13:84-92.
22. Kaufmann SH Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33:567-577.
23. Kaufmann SH, Hussey G, Lambert PH New vaccines for tuberculosis. Lancet 2010, 375:2110-2119.
24. Kaufmann SH Tuberculosis vaccines: time to think about the next generation. Semin Immunol 2013, 25:172-181.
25. Guttstadt A Die Wirksamkeit des Koch'schen Heilmittels gegen Tuberkulose. Klinisches Jahrbuch 1891, Verlag von Julius Springer, Berlin. A. Guttstadt (Ed.).
26. Wolf AJ, Linas B, Trevejo-Nuñez GJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007, 179:2509-2519.
27. Neyrolles O, Hernández-Pando R, Pietri-Rouxel F, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence?. PLoS One 2006, 1:e43.
28. Das B, Kashino SS, Pulu I, et al. CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013, 5:170ra13.
29. Bermudez LE, Goodman J Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 1996, 64:1400-1406.
30. Hawn TR, Matheson AI, Maley SN, Vandal O Host-directed therapeutics for tuberculosis: can we harness the host?. Microbiol Mol Biol Rev 2013, 77:608-627.
31. Rook GA, Lowrie DB, Hernàndez-Pando R Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols?. J Infect Dis 2007, 196:191-198.
32. Rivas-Santiago CE, Hernández-Pando R, Rivas-Santiago B Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers. Immunotherapy 2013, 5:1117-1126.
33. Balu S, Reljic R, Lewis MJ, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011, 186:3113-3119.
34. Reljic R, Ivanyi J Immunotherapy of Tuberculosis with IgA and Cytokines. Understanding Tuberculosis: Analyzing the Origin of Mycobacterium tuberculosis 2012, 457-473. Intech, Pathogenicity. P.J. Cardona (Ed.).
35. Caws M, Thwaites G, Dunstan S, et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008, 4:e1000034.
36. Berrington WR, Hawn TR Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?. Immunol Rev 2007, 219:167-186.
37. Horne DJ, Randhawa AK, Chau TT, et al. Common polymorphisms in the PKP3-SIGIRR-TMEM16J gene region are associated with susceptibility to tuberculosis. J Infect Dis 2012, 205:586-594.
38. Fu Y, Yi Z, Wu X, Li J, Xu F Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol 2011, 49:4246-4251.
39. Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology 2012, 17:772-791.
40. Schoeman JF, Springer P, van Rensburg AJ, et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004, 19:250-257.
41. Fu LM, Fu-Liu CS Thalidomide and tuberculosis. Int J Tuberc Lung Dis 2002, 6:569-572.
42. Tsenova L, Mangaliso B, Muller G, et al. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002, 46:1887-1895.
43. Fukutomi Y, Maeda Y, Makino M Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother 2011, 55:4000-4005.
44. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013, 17:1001-1007.
45. Grosset JH, Tyagi S, Almeida DV, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013, 188:608-612.
46. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013, 68:284-293.
47. Yoo JW, Lyu J, Lee SD, Kim WS, Kim DS, Shim TS Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence]. Int J Tuberc Lung Dis 2013, 17:1243-1244.
48. Critchley JA, Young F, Orton L, Garner P Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:223-237.
49. Iijima H, Shinzaki S, Takehara T The importance of vitamins D and K for the bone health and immune function in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2012, 15:635-640.
50. Campbell GR, Spector SA Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012, 8:e1002689.
51. Verway M, Bouttier M, Wang TT, et al. Vitamin D induces interleukin-1β expression: paracrine macrophage epithelial signaling controls M tuberculosis infection. PLoS Pathog 2013, 9:e1003407.
52. Liu PT, Stenger S, Tang DH, Modlin RL Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007, 179:2060-2063.
53. Haller L, Sossouhounto R, Coulibaly IM, et al. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy 1999, 45:452-465.
54. Giammarioli AM, Maselli A, Casagrande A, et al. Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res 2008, 68:5291-5300.
55. Dai C, Zhang B, Liu X, et al. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. Int J Cancer 2013, 133:1982-1993.
56. Takakura A, Nelson EA, Haque N, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 2011, 20:4143-4154.
57. Manca C, Koo MS, Peixoto B, Fallows D, Kaplan G, Subbian S Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS One 2013, 8:e74082.
58. Condos R, Rom WN, Schluger NW Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997, 349:1513-1515.
59. Koh WJ, Kwon OJ, Suh GY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004, 19:167-171.
60. Dawson R, Condos R, Tse D, et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One 2009, 4:e6984.
61. Gao XF, Yang ZW, Li J Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis 2011, 15:e594-e600.
62. Suárez-Méndez R, García-García I, Fernández-Olivera N, et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 2004, 4:44.
63. Johnson BJ, Ress SR, Willcox P, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther 1995, 1:185-196.
64. Johnson B, Bekker LG, Ress S, Kaplan G Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis. Novartis Found Symp 1998, 217:99-106.
65. Johnson BJ, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 1997, 78:195-203.
66. Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003, 168:185-191. the Uganda-Case Western Reserve University Research Collaboration.
67. Pedral-Sampaio DB, Netto EM, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis 2003, 7:245-252.
68. Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?. Expert Rev Vaccines 2010, 9:519-525.
69. Giosuè S, Casarini M, Ameglio F, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000, 11:99-104.
70. Palmero D, Eiguchi K, Rendo P, Castro Zorrilla L, Abbate E, González Montaner LJ Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999, 3:214-218.
71. Greinert U, Ernst M, Schlaak M, Entzian P Interleukin-12 as successful adjuvant in tuberculosis treatment. Eur Respir J 2001, 17:1049-1051.
72. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
73. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208:199-202.
74. Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013, 3:e002672.
75. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
76. Jacquel A, Herrant M, Legros L, et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 2003, 17:2160-2162.
77. Eklund KK, Joensuu H Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003, 35:362-367.
78. Wolf AM, Wolf D, Rumpold H, et al. The kinase inhibitor imatinib mesylate inhibits TNF-alpha production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 2005, 102:13622-13627.
79. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006, 116:2633-2642.
80. Napier RJ, Rafi W, Cheruvu M, et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011, 10:475-485.
81. Maiga M, Agarwal N, Ammerman NC, et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One 2012, 7:e30749.
82. Maiga M, Ammerman NC, Maiga MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013, 208:512-519.
83. Roca FJ, Ramakrishnan L TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013, 153:521-534.
84. Ververis K, Hiong A, Karagiannis TC, Licciardi PV Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013, 7:47-60.
85. Marks PA The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19:1049-1066.
86. Ji MH, Li GM, Jia M, et al. Valproic acid attenuates lipopolysaccharide-induced acute lung injury in mice. Inflammation 2013, 36:1453-1459.
87. Licciardi PV, Ververis K, Tang ML, El-Osta A, Karagiannis TC Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med 2013, 13:640-647.
88. Wagner JM, Hackanson B, Lübbert M, Jung M Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010, 1:117-136.
89. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004, 18:1101-1108.
90. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009, 23:1799-1806.
91. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
92. Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 2013, 9:790-799.
93. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013, 21:277-285.
94. Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013, 9:993-1001.
95. Wu SN, Li HF, Jan CR, Shen AY Inhibition of Ca2+-activated K+ current by clotrimazole in rat anterior pituitary GH3 cells. Neuropharmacology 1999, 38:979-989.
96. Brugnara C, de Franceschi L, Alper SL Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993, 92:520-526.
97. De Franceschi L, Saadane N, Trudel M, Alper SL, Brugnara C, Beuzard Y Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest 1994, 93:1670-1676.
98. Benzaquen LR, Brugnara C, Byers HR, Gatton-Celli S, Halperin JA Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med 1995, 1:534-540.
99. Badri M, Wilson D, Wood R Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064.
100. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012, 9:e1001270.
101. Naidoo K, Baxter C, Abdool Karim SS When to start antiretroviral therapy during tuberculosis treatment?. Curr Opin Infect Dis 2013, 26:35-42.
102. Choi AM, Ryter SW, Levine B Autophagy in human health and disease. N Engl J Med 2013, 368:651-662.
103. Levine B Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell 2005, 120:159-162.
104. Watson RO, Manzanillo PS, Cox JS Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012, 150:803-815.
105. Romagnoli A, Etna MP, Giacomini E, et al. ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells. Autophagy 2012, 8:1357-1370.
106. Bahari G, Hashemi M, Taheri M, Naderi M, Eskandari-Nasab E, Atabaki M Association of IRGM polymorphisms and susceptibility to pulmonary tuberculosis in Zahedan, Southeast Iran. Scientif World J 2012, 2012:950801.
107. King KY, Lew JD, Ha NP, et al. Polymorphic allele of human IRGM1 is associated with susceptibility to tuberculosis in African Americans. PLoS One 2011, 6:e16317.
108. Intemann CD, Thye T, Niemann S, et al. Autophagy gene variant IRGM-261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M africanum strains. PLoS Pathog 2009, 5:e1000577.
109. MacMicking JD, Taylor GA, McKinney JD Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003, 302:654-659.
110. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124. the International IBD Genetics Consortium (IIBDGC).
111. Singh SB, Davis AS, Taylor GA, Deretic V Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006, 313:1438-1441.
112. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007, 39:830-832. the Wellcome Trust Case Control Consortium.
113. Castillo EF, Dekonenko A, Arko-Mensah J, et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci USA 2012, 109:E3168-E3176.
114. Harris J, De Haro SA, Master SS, et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007, 27:505-517.
115. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766.
116. Kim JJ, Lee HM, Shin DM, et al. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 2012, 11:457-468.
117. Simmons CP, Thwaites GE, Quyen NT, et al. Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome. J Immunol 2006, 176:2007-2014.
118. Misra UK, Kalita J, Nair PP Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci 2010, 293:12-17.
119. Bourigault ML, Vacher R, Rose S, et al. Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. Am J Clin Exp Immunol 2013, 2:124-134.
120. Skerry C, Harper J, Klunk M, Bishai WR, Jain SK Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One 2012, 7:e39680.
121. Skrahin A, Ahmed R, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2:108-122.
122. Lee HK, Mattei LM, Steinberg BE, et al. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity 2010, 32:227-239.
123. Rubinsztein DC, Codogno P, Levine B Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012, 11:709-730.
124. Levine B, Mizushima N, Virgin HW Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
125. Deretic V, Levine B Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009, 5:527-549.
126. Kumar D, Nath L, Kamal MA, et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 2010, 140:731-743.
127. Levine B, Klionsky DJ Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
128. Holla S, Kurowska-Stolarska M, Bayry J, Balaji KN Selective inhibition of IFNG-induced autophagy by Mir155- and Mir31-responsive WNT5A and SHH signaling. Autophagy 2014, 10:311-330.
129. Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol 2011, 12:861-869.
130. Rajaram MV, Ni B, Morris JD, et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci USA 2011, 108:17408-17413.
131. Singh Y, Kaul V, Mehra A, et al. Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity. J Biol Chem 2013, 288:5056-5061.
132. Dorhoi A, Iannaccone M, Farinacci M, et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 2013, 123:4836-4848.
133. Wang C, Yang S, Sun G, et al. Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS One 2011, 6:e25832.
134. Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451:1125-1129.
135. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 2008, 39:127-132.
136. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature 2009, 460:98-102.
137. Tobin DM, Vary JC, Ray JP, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-730.
138. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003, 138:819-830.
139. Goldman JM, Melo JV Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
140. Zipfel PA, Zhang W, Quiroz M, Pendergast AM Requirement for Abl kinases in T cell receptor signaling. Curr Biol 2004, 14:1222-1231.
141. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003, 22:329-332.
142. O'Kane CM, Elkington PT, Jones MD, et al. STAT3, p38 MAPK, and NF-kappaB drive unopposed monocyte-dependent fibroblast MMP-1 secretion in tuberculosis. Am J Respir Cell Mol Biol 2010, 43:465-474.
143. Buonsenso D, Serranti D, Valentini P Management of central nervous system tuberculosis in children: light and shade. Eur Rev Med Pharmacol Sci 2010, 14:845-853.
144. Kadhiravan T, Deepanjali S Role of corticosteroids in the treatment of tuberculosis: an evidence-based update. Indian J Chest Dis Allied Sci 2010, 52:153-158.
145. Madonna S, Scarponi C, Pallotta S, Cavani A, Albanesi C Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis 2012, 3:e334.
146. Kleinsteuber K, Heesch K, Schattling S, et al. SOCS3 promotes interleukin-17 expression of human T cells. Blood 2012, 120:4374-4382.
147. Carow B, Reuschl AK, Gavier-Widén D, et al. Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis. PLoS Pathog 2013, 9:e1003442.
148. Ahmad Z, Sharma S, Khuller GK In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 2005, 251:19-22.
149. McLean KJ, Marshall KR, Richmond A, et al. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 2002, 148:2937-2949.
150. Xiao YF, Huang L, Morgan JP Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol 1998, 508:777-792.
151. Muñoz-Planillo R, Kuffa P, Martínez-Colón G, Smith BL, Rajendiran TM, Núñez G K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38:1142-1153.
152. Nguyen LT, Haney EF, Vogel HJ The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol 2011, 29:464-472.
153. Kai-Larsen Y, Agerberth B The role of the multifunctional peptide LL-37 in host defense. Front Biosci 2008, 13:3760-3767.
154. Sow FB, Nandakumar S, Velu V, et al. Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin. Tuberculosis (Edinb) 2011, 91:314-321.
155. Elyamany G, Alzahrani A Hepcidin: an overview. J Appl Haematol 2013, 2:46-52.
156. Klug-Micu GM, Stenger S, Sommer A, et al. CD40 ligand and interferon-γ induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes. Immunology 2013, 139:121-128.
157. Andreu D, Carreño C, Linde C, Boman HG, Andersson M Identification of an anti-mycobacterial domain in NK-lysin and granulysin. Biochem J 1999, 344:845-849.
158. Mueller H, Faé KC, Magdorf K, et al. Granulysin-expressing CD4+ T cells as candidate immune marker for tuberculosis during childhood and adolescence. PLoS One 2011, 6:e29367.
159. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007, 117:1988-1994.
160. Wherry EJ T cell exhaustion. Nat Immunol 2011, 12:492-499.
161. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
162. Qiu Y, Chen J, Liao H, et al. Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog 2012, 8:e1002984.
163. Jayaraman P, Sada-Ovalle I, Beladi S, et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med 2010, 207:2343-2354.
164. Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008, 181:116-125.
165. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
166. O'Neill LA, Hardie DG Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493:346-355.
167. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
168. Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011, 208:1367-1376.
169. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011, 365:2055-2066.
170. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013, 5:179ra43.
171. Holt PG, Strickland DH, Wikström ME, Jahnsen FL Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008, 8:142-152.
172. Corrales-Garcia L, Ortiz E, Castañeda-Delgado J, Rivas-Santiago B, Corzo G Bacterial expression and antibiotic activities of recombinant variants of human β-defensins on pathogenic bacteria and M. tuberculosis. Protein Expr Purif 2013, 89:33-43.
173. Ottenhoff TH, Kaufmann SH Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog 2012, 8:e1002607.
174. Prabowo SA, Gröschel MI, Schmidt ED, et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol (Berl) 2013, 202:95-104.
175. Cardona PJ RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006, 86:273-289.
176. de Bruyn G, Garner P Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003, 1. CD001166.
177. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24:675-685. DarDar Study Group.
178. Yang XY, Chen QF, Li YP, Wu SM Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011, 6:e23826.
179. Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One 2012, 7:e39215.
180. Kaufmann SH, Gengenbacher M Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012, 23:900-907.
181. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
182. Arbues A, Aguilo JI, Gonzalo-Asensio J, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013, 31:4867-4873.
183. Palmer M The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 2001, 39:1681-1689.
184. Decatur AL, Portnoy DA A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290:992-995.
185. Walker KB, Brennan MJ, Ho MM, et al. The second Geneva Consensus: recommendations for novel live TB vaccines. Vaccine 2010, 28:2259-2270.
186. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028. MVA85A 020 Trial Study Team.
187. Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013, 5:205ra134.
188. Radosevic K, Wieland CW, Rodriguez A, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007, 75:4105-4115.
189. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013, 369:2083-2092. the HVTN 505 Study Team.
190. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893. the Step Study Protocol Team.
191. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011, 11:507-515. the HVTN 503/Phambili study team.
192. Montoya J, Solon JA, Cunanan SR, et al. A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013, 33:1360-1375.
193. van Dissel JT, Arend SM, Prins C, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 2010, 28:3571-3581.
194. van Dissel JT, Soonawala D, Joosten SA, et al. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
195. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99.
196. Lingnau K, Riedl K, von Gabain A IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007, 6:741-746.
197. Christensen D, Foged C, Rosenkrands I, et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int J Pharm 2010, 390:19-24.
198. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
199. Houghton J, Cortes T, Schubert O, et al. A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection. PLoS One 2013, 8:e80047.
200. Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2:53ra74.
201. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853-13858.
202. Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
203. Kupferschmidt K Infectious disease. Taking a new shot at a TB vaccine. Science 2011, 334:1488-1490.
204. Sun R, Skeiky YA, Izzo A, et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27:4412-4423.
205. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010, 17:1763-1771.
206. Leroux-Roels I, Forgus S, De BF, et al. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013, 31:2106-2196.
207. Montoya J, Solon JA, Cunanan SR, et al. A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013, 33:1360-1375.
208. Spertini F, Audran R, Lurati F, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis (Edinb.) 2013, 93:179-188.
209. Frick M The TB vaccines pipeline: where are we going, where have we been? 2013, 263-283. HIV i-Base and Treatment Action Group, London.
210. Grode L, Ganoza CA, Brohm C, Weiner J, Eisele B, Kaufmann SH Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013, 31:1340-1348.
211. Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010, 28:1106-1116.
212. Gupta A, Ahmad FJ, Ahmad F, et al. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine 2012, 30:6198-6209.
213. Schwander S, Dheda K Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 2011, 183:696-707.